The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...

Lexicon's LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down ...

Novo Nordisk already has a fairly well-stocked pipeline of candidates, but one of its near-term hopes – CagriSema, which combines semaglutide with dual amylin and calcitonin receptor agonist ...

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

Now drugmakers are experimenting with the use of other related pathways called glucagon and amylin — although Novo’s initial effort in that area, combining GLP-1 and amylin, has underperformed ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

“The addition of a candidate targeting glucagon, as well as GLP-1 and GIP ... a peptide engineered to target the amylin receptor. Also, the triple agonist did not reach the desired target ...

Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of ...

"The addition of a candidate targeting glucagon, as well as GLP-1 and GIP ... a nascent form of weight loss treatment known as an amylin analog — and semaglutide, the active ingredient in ...

Novo Nordisk stock dropped Monday after the drugmaker licensed a Chinese competitor's weight-loss drug for $200 million up ...